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Ischaemic heart disease persists as the leading global cause of death 
and lost life years in adults.1 Angina is a common clinical presentation 
of ischaemic heart disease related to a supply:demand mismatch 
of myocardial blood flow, typically provoked by exertion or stress. 
Invasive coronary angiography is the reference test for angina and 
identifies obstructive coronary artery disease (CAD) as a cause for 
symptoms. In Europe and the US, approximately 4 million elective 
coronary angiograms are performed each year.2,3 However, up to half 
of all angina patients undergoing elective coronary angiography with 
symptoms and/or signs of ischaemia have no obstructive epicardial 
coronary artery disease (INOCA).3 This large, heterogeneous group 
includes patients with microvascular angina (MVA), vasospastic angina 
(VSA) or both conditions together. The burden of these conditions on 
physical and mental wellbeing can be profound; they are associated 
with morbidity4 and a reduction in quality of life.5 Patients with these 
conditions commonly attend primary and secondary care, driving up 
health resource utilisation.6 
We propose that optimal clinical management starts with the correct 
diagnosis; hence we begin by summarising the rationale and protocol 
for invasive tests of coronary function in INOCA patients. We discuss 
drivers of myocardial ischaemia and reappraise existing consensus 
guideline-based management in light of the CORonary MICrovascular 
Angina (CorMicA) study, the first randomised controlled trial of 
invasive coronary function testing linked to stratified medical therapy 
in angina. This review aims to educate and empower the invasive 
cardiologist to perform vasoreactivity testing and to provide them with 
an understanding of the positive impact of personalised medicine for 
individual angina patients. We conclude pointing to future directions 
in care and the benefits of improved diagnosis linked to translational 
clinical research to develop targeted disease-modifying therapy.
Background and Aetiology of Angina Without 
Obstructive Coronary Disease
INOCA is a recently proposed ‘umbrella’ term conveying the 
importance of stable coronary syndromes beyond obstructive CAD 
(Figure 1). INOCA aligns with the sibling term MINOCA, which stands for 
myocardial infarction with no obstructive CAD. MINOCA is a similarly 
diverse syndrome with distinct underlying causes.7 
Depending on the patient population studied and the techniques 
used, between one-third and two-thirds of angina patients with a 
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negative angiogram have an underlying disorder of coronary vascular 
function.8,9 Importantly, the two most common causes of INOCA 
(MVA and VSA) are not excluded by a negative non-invasive CT 
coronary angiogram or invasive coronary angiogram.6 For affected 
patients, symptom burden, morbidity and health resource utilisation 
can be considerable.5,10,11 
As cardiologists, we often adopt a ‘stenosis-centric’ approach. 
However, as clinicians we must appreciate the complexity and 
individual contributors to ischaemia in patients without obstructive 
epicardial disease (Figure 1). Systemic factors, including heart rate, 
blood pressure (and their product) and myocardial supply:demand 
ratio (Buckberg index), are important.12,13 Coronary factors are well 
recognised, but certain nuances are overlooked. For example, Gould 
and Johnson recently used their quantitative myocardial perfusion 
database of over 5,900 patients to show that occult coronary 
diffuse obstructive coronary disease or flush ostial stenosis may 
be overlooked on angiography and mislabelled as microvascular 
angina with suboptimal treatment.14 Other coronary factors that 
can cause ischaemia and propensity to acute coronary syndromes 
include structural microvascular dysfunction, endothelial impairment, 
myocardial bridging and/or epicardial vasospasm.15,16
The final group of factors that can drive INOCA is cardiac, including 
left ventricular hypertrophy or restrictive cardiomyopathy where 
subendocardial ischaemia results from challenges with arteriolar 
vessels penetrating deeper into the myocardial tissue with shorter 
diastole and enhanced systolic myocardial vessel constriction.17 
Heart failure (with reduced or preserved ejection fraction) can lead 
to elevated left-ventricular end diastolic pressures that reduce the 
physiological myocardial perfusion gradient. 
Valvular heart disease, e.g. aortic stenosis or left ventricular outflow tract 
obstruction, is a well-recognised cause of INOCA, although controversy 
exists over whether symptoms in mechanical outflow tract obstruction 
(aortic stenosis) relate to microvascular dysfunction, supply:demand 
factors or both.18 Most experts support haemodynamic factors as the 
main cause of ischaemia here, especially since symptoms and coronary 
flow reserve improve immediately after valve replacement.19
Non-invasive Functional Testing
Non-invasive tests provide indirect assessments of myocardial 
resistance by assessing perfusion during exercise or pharmacological 
stress, typically using systemic adenosine. Nevertheless, perfusion 
assessment lacks the sensitivity to diagnose the relative contributions 
of epicardial and microvascular disease to myocardial blood 
flow reduction. In addition, some patients with a propensity to 
vasospastic chest pain syndromes may have normal findings from 
pharmacological and exercise stress testing. This review focuses 
on the invasive diagnosis and related management of angina 
subjects without obstructive disease; the non-invasive workup is 
covered elsewhere.20,21
Diagnosis and Rationale for Invasive Testing
In the cardiac catheterisation laboratory, coronary vascular function 
may be assessed ad hoc during the patient’s index coronary angiogram. 
This often involves an interventional diagnostic procedure (IDP) where 
a guidewire-based assessment of coronary blood flow is performed at 
rest and during interrogation with pharmacological probes, typically 
adenosine and acetylcholine. 
The rationale for an IDP is three-fold. First, these patients often present 
with typical angina for invasive coronary angiography, which offers an 
opportunity for the cardiologist to provide patients with an accurate 
diagnosis and explanation for their symptoms. Second, discrimination 
of MVA, VSA and non-cardiac chest pain permits distinct treatment 
outlined in consensus practice guidelines. Third, evidence of coronary 
vascular dysfunction carries prognostic insights for patients and their 
clinicians. However, in contemporary standard practice, additional 
invasive tests on patients with unobstructed coronary arteries are very 
rarely performed. 
The IDP consists of two steps: assessment of coronary circulation 
vasorelaxation using invasive coronary physiology at rest and with 
hyperaemia; and second, assessment of the propensity of the 
coronary circulation to excessive vasoconstriction using intra-arterial 
acetylcholine (microvascular and/or epicardial vasospasm) (Table 1). 
We typically prefer the left anterior descending coronary artery as the 
target vessel because it subtends the largest myocardial mass. While 
regional microvascular dysfunction is well recognised, interrogation 
of multiple vessels increases the procedural duration such that the 
benefits of testing may be outweighed by the risks. 
Assessment of Coronary Vasorelaxation and 
Resistance Using Diagnostic Guidewire 
The purpose of step one is to assess the coronary flow reserve 
(CFR) and microvascular resistance, typically using the index of 
microcirculatory resistance (IMR; Figure 2). Flow-limiting epicardial 
coronary disease may be assessed using fractional flow reserve 
(FFR), which is the ratio of mean distal coronary pressure to mean 
aortic pressure at maximal hyperaemia. Abnormal FFR is defined as 
≤0.80 or alternatively a non-hyperaemic pressure ratio with different 
cut-off may be used, e.g. diastolic-only pressure ratio.22,23 The CFR is 
determined by dividing the hyperaemic coronary blood flow by the 
resting flow. This is also termed the vasodilator capacity and reflects 
the ability of the coronary circulation to augment blood flow from rest. 
CFR is calculated using thermodilution as the resting mean transit 
time divided by hyperaemic mean transit time; an abnormal CFR is 
defined as ≤2.24,25 Microcirculatory resistance can be assessed using 
Figure 1: Ischaemia with No Obstructive Coronary Artery 
Disease: A Coronary Syndrome
INOCA
1
Systemic factors
• Myocardial supply: demand ratio
(SEVR or Buckberg index)
• Pulse rate
• Blood pressure
• Heightened sympathetic activation
2
Coronary factors
• Microvascular dysfunction
• Endothelial impairment
• Occult diffuse epicardial CAD
• Coronary artery spasm
• Myocardial bridging
3
Cardiac factors
• Impaired diastolic relaxation
• Left ventricular hypertrophy
• Diastolic dysfunction
• Valvular heart disease
• Left ventricular outflow tract
 obstruction
1
2
3
The traditional paradigm where angina is ubiquitously associated with obstructive epicardial 
disease overlooks the importance other determinants of myocardial ischaemia. These three 
groups of factors combine to determine the physiological myocardial perfusion gradient.  
CAD = coronary artery disease; INOCA = ischaemia but no obstructive coronary artery 
disease; SEVR = subendocardial viability ratio.
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thermodilution or Doppler. The IMR is calculated as the distal coronary 
pressure at maximal hyperaemia multiplied by the hyperaemia mean 
transit time.26 Increased IMR (≥25) is representative of microvascular 
dysfunction.27 If Doppler wires are used, the hyperaemic microvascular 
resistance may be calculated as the ratio between hyperaemia 
distal coronary pressure and hyperaemia average peak velocity, with 
measurements >2.5 mmHg/cm/s being abnormal.28 
In brief, 50–70 U/kg intravenous heparin should be administered and 
a guiding catheter used to engage the coronary artery. We induce 
hyperaemia pharmacologically with intravenous adenosine 140 μg/
kg/minute, although other pharmacological agents or exercise may 
be used. A pressure–temperature sensor guidewire (PressureWire X™, 
Abbott Vascular) or a Doppler wire (ComboWire XT® or FloWire®, Philips 
Volcano Corporation) may be used. In this technique, the guidewire 
wirelessly transmits data to a workstation or computer using dedicated 
analysis software (e.g. CoroFlow™, Coroventis). Typically, intra-arterial 
glyceryl trinitrate is given as for standard FFR assessment, although 
we suggest using ≤200 μg. The half-life of glyceryl trinitrate is around 
2 minutes; thus after 10 minutes only 3% of the medication is active 
and it is unlikely to suppress a false-positive test for vasospasm in step 
two. Conversely if acetylcholine (ACh) testing is performed first, then 
resting flow and CFR assessment may be inaccurate, particularly after 
a positive vasospasm test. 
After equalisation and passing the diagnostic guidewire into the 
distal third of the vessel, the blood flow at rest is assessed either by 
thermodilution (akin to right heart catheterisation with Swan–Ganz/
bolus of normal saline) or by Doppler wire. 
Assessment for Propensity to Coronary 
Vasoconstriction: Acetylcholine Provocation
In healthy endothelium, ACh stimulates abluminal release of nitric oxide, 
mediating vascular smooth muscle relaxation and increased blood flow. 
At high doses or in patients with endothelial dysfunction, ACh directly 
stimulates vascular smooth muscle, causing vasoconstriction that can 
precipitate epicardial vasospasm and/or microvascular vasospasm-
induced ischaemia. Typically, infusions of ACh at concentrations 
approximating 0.182, 1.82, and 18.2 µg/ml (10−6, 10−5 and 10−4 mol/l, 
respectively) at 1 ml/min for 2–3 minutes are given via a mechanical 
pump. These doses were historically derived using experiments adopting 
subselective infusion through an infusion catheter into the left anterior 
descending artery, assuming a resting flow of 80 ml/min. The effective 
concentration at tissue level was estimated at 10−8 to 10−6 M. The 
assessment of Doppler response to ACh involves intracoronary infusion 
catheters in combination with Doppler wire and requires larger guiding 
catheter sizes (7 Fr) and a 3 Fr infusion catheter into the coronary artery. 
Centres in Japan with over four decades of experience with ACh 
testing adopt a pragmatic and streamlined approach using sequential 
bolus doses of ACh via the guiding catheter. Doses start from 20 µg, 
increasing to 50 and 100 up to 200 µg in the left system (or 20, 50 
and 80 µg into the right coronary) over 20 seconds followed by up 
to 3 minutes between doses.29 Coronary angiography is performed 
when either ST segment changes or chest pain (or both) occur, 
or after 1 minute following the completion of each injection. We 
routinely use a well-engaged guiding catheter to deliver ACh via a 
2-minute infusion using an external mechanical pump without an 
additional infusion catheter. This approach facilitates smaller guiding 
catheters and reduces risk, time and procedural cost. 
Figure 2: Interventional Diagnostic Procedure in Ischaemia 
with No Obstructive Coronary Artery Disease for 
Diagnosis and Stratified Management
Diagnostic
guidewire
(adenosine)
Invasive
coronary
angiography
Vasoreactivity
(acetylcholine)
Diagnosis and
management
No substrate for angina:
(FFR 0.84, CFR 5.3, IMR 9)
No obstructive CAD
Vasospasm with ACh
(resolves with nitrate)
Vasospastic Angina
• Calcium channel blocker
• Long-acting nitrate
• Avoid betablockers
• Smoking cessation
• Lifestyle factors and
 cardiac rehabilitation
No obstructive CAD
Microvascular dysfunction
(FFR 0.95, CFR 1.3, IMR 33)
Endothelial dysfunction
without vasospasm to ACh
Microvascular Angina
• Beta-blocker
• Consider an ACEI or statin
• Smoking cessation
• Weight loss, cardiac 
   rehabilitation
• Avoid long-acting nitrates
ACh GTN ACh GTN
ACEI = angiotensin-converting enzyme inhibitor; ACh = acetylcholine; CAD = coronary 
artery disease; FFR = fractional flow reserve; GTN = glyceryl trinitrate; IMR = index of 
microcirculatory resistance.
Table 1: Definition and Invasive Diagnostic Criteria for Disorders of Coronary Artery Function
Disorder Symptoms Clinical measurement
Microvascular angina Abnormal microvascular resistance • IMR ≥2527
• Hyperaemic microvascular resistance ≥2.5 mmHg/cm/s28
Impaired coronary vasorelaxation • CFR by thermodilution <2.025
Microvascular spasm Angina symptoms with ACh infusion AND:
• ST-segment deviation on ECG
• No significant epicardial coronary spasm (<90% diameter reduction) 
Vasospastic angina Epicardial spasm Angina symptoms during ACh bolus (e.g. 100 μg acetylcholine over 20 seconds) AND:
• ST-segment deviation on ECG
• >90% epicardial coronary constriction during ACh reduction34
Non-cardiac •  Exclusion of significant epicardial coronary disease (fractional flow reserve >0.8) 
without any of the following abnormalities of coronary function: CFR <2.0,  
IMR ≥25 or positive ACh response.
ACh = acetylcholine; CFR = coronary flow reserve; IMR = index of microvascular resistance.
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Epicardial coronary artery spasm is defined according to the Coronary 
Vasomotion Disorders International Study Group criteria whereby 
chest pain is reproduced with ST segment deviation and ≥90% 
vasoconstriction to 100 µg of ACh (5.5 ml of 10−4 M over 20 seconds). 
Microvascular spasm is defined chest pain and ST segment deviation 
without significant luminal constriction (<90%) and represents 
a functional subtype of microvascular angina. Severe epicardial 
endothelial dysfunction is defined by ≥20% luminal constriction 
during ACh infusion (up to 10−4 M); this finding implies a significant 
reduction in coronary artery blood flow with prognostic implications 
when compared with patients whose arteries are <20% constricted.30 
Bradycardia with ACh is common and usually self-limiting, although 
a reduced dose during interrogation of the right coronary artery 
(maximum 50–80 μg ACh) may reduce occurrence.
CorMicA and Clinical Evidence
Despite a wealth of clinical evidence from observational studies, 
until recently there has not been a single randomised controlled 
trial of coronary function testing. In the absence of randomised trials 
demonstrating patient benefits, observational evidence has rarely been 
applied in practice. CorMicA now provides proof-of-concept clinical 
evidence to support the case for patient benefits when management 
is guided by invasive tests of coronary artery function (IDP). Ad hoc 
adoption of coronary function testing for patients with INOCA is 
currently restricted to a few interested academic centres. In part this 
relates to lack of evidence that an IDP has clinical utility or improves 
patient well-being. 
Supported by the British Heart Foundation and the patients who kindly 
agreed to take part, we delivered the CorMicA trial to specifically 
address this gap in evidence.31,32 We hypothesised that stratified 
medicine, including an IDP with linked medical therapy, would be 
routinely feasible and lead to improvements in angina and quality of 
life in patients with no obstructive CAD. 
A total of 391 patients with definite or probable angina, as 
determined on the Rose angina questionnaire,were enrolled over 
a 12-month period from November 2016 at two large tertiary 
referral centres serving around half the population of Scotland 
(approximately 2.5 million people).33 Coronary angiography revealed 
no obstructive CAD in 185 (47%) of the patients who completed 
the Rose questionnaire and 151 individuals were immediately 
randomised to one of two arms: the intervention group (stratified 
medical therapy, IDP disclosed) or the control group (standard care, 
IDP sham procedure, results not disclosed). The mean age of subjects 
was 62 years and 74% were female. 
The diagnostic intervention included a guidewire-based assessment of 
a major coronary artery, usually the left anterior descending coronary 
artery, followed by pharmacological coronary reactivity testing 
(Figure 2). This diagnostic assessment aligned with contemporary 
guidelines.34,35 The IDP involved measurement of CFR (abnormal <2.0), 
microcirculatory resistance (IMR; abnormal ≥25) and FFR (abnormal 
≤0.80). Vasoreactivity testing was then performed by infusing incremental 
concentrations of ACh followed by a bolus of ACh of up to 100 μg to 
assess for epicardial or microvascular vasospasm. The diagnosis of 
a clinical endotype (MVA, VSA, both or none) was linked to distinct 
guideline-based management stratified by diagnosis.36 The primary 
endpoint was the mean difference in angina severity at 6 months as 
assessed by the Seattle Angina Questionnaire summary score.37
In an all-comers study design, the IDP revealed isolated MVA 
in 78 subjects (52%), isolated VSA in 25 subjects (17%), mixed 
angina (both) in 31 subjects (20%) and non-cardiac chest pain in 
17 subjects (11%) (Figure 3). The intervention was associated with 
a mean improvement of 11.7 units in Seattle Angina Questionnaire 
summary score at 6 months (95% CI [5.0–18.4], p=0.001). In addition, 
the intervention led to improvements in the mean quality of life 
score (EQ-5D index 0.10 units; 95% CI [0.01–0.18]; p=0.024) and 
visual analogue score (14.5 units; 95% CI [7.8–21.3]; p<0.001).31 
Notably, after the disclosure of coronary function testing, over 
half of the treating clinicians changed their diagnosis. There were 
no differences in major adverse cardiac events after 6 months of 
follow-up (2.6% controls versus 2.6% intervention; p=1.00). Thus, we 
showed that in patients undergoing invasive coronary angiography, 
obstructive coronary disease is excluded in half of all patients; 
and within this large group of patients, the majority have a readily 
identifiable disorder of coronary vasomotion. Specifically, the 
IDP with linked medical therapy was routinely feasible and safe, 
resulting in improvements in angina and quality of life at 6 months 
in this group of patients. CorMicA was undertaken in a real-world 
setting and the results appear to be transferable to clinical practice. 
Future trials are anticipated to determine the wider external validity 
of this approach.
Stratified Medicine in Angina
We start by considering the patient in the context of non-coronary 
contributors to INOCA (Figure 1). Non-pharmacological therapies 
encompassing lifestyle modification, risk factor control, evidence-
based pharmacological therapy and patient education are also 
essential for stratifying treatment. Lifestyle recommendations are 
covered in detail in the recent European Society of Cardiology 
guidelines.38 We will focus on the two most common diagnostic 
groups to guide distinct medical treatments.
Microvascular Angina 
The diagnosis of MVA may be suspected in angina patients without 
obstructive CAD who have evidence of microvascular dysfunction. 
In the IDP above, microvascular dysfunction consists of abnormal 
CFR (<2.0), abnormal IMR (≥25) and/or microvascular spasm during 
ACh provocation. Clearly, this is a heterogenous entity akin to the 
syndrome of heart failure with preserved ejection fraction (HFpEF) 
with diverse aetiology.39
Figure 3: Prevalence and Treatment of Ischaemia with No 
Obstructive Coronary Artery Disease
MVA 52%
VSA 17%
Mixed (both) 20%
Non-cardiac 11%
A B
3rd
2nd
1st
Ca2+
antagonist
Nitrate
Nicorandil
Beta-blocker
Ca2+
antagonist
Ranolazine Nicorandil
Vasospastic
angina
Microvascular
angina
Consider statin and ACEI
A:The overall prevalence of coronary artery vasomotion disorders in the CorMicA study.  
B: Authors’ interpretation of the evidence for recommended therapy for angina patients 
without obstructive CAD stratified by diagnosis. This formed the basis of pharmacological 
treatment for patients in the British Heart Foundation CorMicA study. ACEI = angiotensin-
converting enzyme inhibitor; MVA = microvascular angina; VSA = vasospastic angina.
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Baseline “disease-modifying” therapies that have demonstrated benefit 
in clinical trials of microvascular angina include angiotensin-converting 
enzyme inhibitors40 and statins.41 We particularly support these baseline 
therapies in patients with diffuse CAD without epicardial obstruction. 
European Society of Cardiology guidelines for patients with MVA 
recommend beta-blockers as first-line and calcium antagonists if the 
former are not tolerated or efficacious (Table 2).36 Dihydropyridine 
calcium blockers, e.g. amlodipine 5–10 mg, may be added to beta-
blockers if blood pressure permits. There is accumulating evidence that 
long-acting nitrates are ineffective or even detrimental in MVA.42 Lack of 
efficacy may relate to poor tolerability, steal syndromes through regions 
of adequately perfused myocardium and/or related to the reduced 
responsiveness of nitrates within the coronary microcirculation.43 There 
is significant clinical overlap between MVA and HFpEF,44 so inferences 
about nitrate response may be drawn from the Nitrate’s Effect on 
Activity, Tolerance in HFpEF (NEAT-HFpEF) study. In this randomised 
controlled trial, HFpEF patients on isosorbide mononitrate actually did 
worse with reduced activity levels assessed using an accelerometer.45 
Ranolazine is a relatively new and well-researched antianginal 
therapy that may improve myocardial perfusion by decreasing sodium 
and calcium overload, thereby improving myocyte relaxation and 
ventricular compliance.46 In a randomised placebo-controlled clinical 
trial of ranolazine led by the Women’s Ischemic Syndrome Evaluation 
investigators, although there were no overall improvements in angina 
and myocardial perfusion with ranolazine, patients with a reduced 
CFR (<2.5) benefitted from ranolazine, with significant improvements 
in myocardial perfusion (p=0.014) and angina frequency (p=0.027).47 
Multiple other drugs that reduce angina may be added, including 
nicorandil and ivabradine.21 
Vasospastic Angina 
VSA is often characterised by rest angina, often with preserved 
effort tolerance. The poor nitrate response or tolerance seen in MVA 
contrasts with patients with vasospastic angina, in whom nitrates are a 
cornerstone therapy and beta-blockers are relatively contraindicated.36 
Dual pathology (VSA with underlying microvascular disease) 
is not uncommon.48,49 
A positive diagnosis of VSA facilitates treatment using non-
dihydropyridine calcium antagonists, e.g. controlled-release diltiazem 
at up to 500 mg daily, which are usually very effective. High doses of 
Table 2: Pharmacological and Non-pharmacological Treatment Options for Angina 
Diagnosis Investigation Pathophysiology Treatment Effects
Microvascular angina 
↓ vasorelaxation
↓ CFR and/or ↑ 
microvascular 
resistance
Anatomical remodelling, 
vascular rarefaction, disturbed 
coronary regulation
Beta-blockers (e.g. nebivolol 
2.5–10mg)
↓ myocardial oxygen consumption
ACE inhibitors (e.g. ramipril 
2.5 mg)
Improve CFR, ↓ workload, may improve 
small vessel remodelling 
Ranolazine (e.g. 375 mg twice 
daily)
Improves microvascular perfusion 
reserve index in patients with MVA and 
reduced CFR
Microvascular angina
↑ vasoconstriction
Hyper-reactivity 
to stimuli (e.g. 
acetylcholine, 
exercise, stress) 
Endothelial dysfunction, 
inappropriate pre-arteriolar 
vasoconstriction
Calcium antagonists (e.g. 
amlodipine 10 mg) 
Vascular smooth muscle relaxation, ↓ 
myocardial oxygen consumption
ACE inhibitors (e.g. ramipril 
2.5 mg)
Improves endothelial vasomotor 
dysfunction
Nicorandil (e.g. 5–10mg 
twice daily)
Potassium-channel activator with 
coronary microvascular dilatory effect
Statins (e.g. rosuvastatin 
10–20 mg)
Improve coronary endothelial function, 
pleiotropic effects including reduced 
vascular inflammation
Hormone replacement 
therapy
Oestrogen therapy improves symptoms 
but not proven to improve ischaemia or 
endothelial function
Microvascular angina
Abnormal pain 
processing
↑ nociception Dysfunctional cortical pain 
processing
Tricyclic antidepressants
(e.g. imipramine up to 25 mg)
Improved symptom burden potentially 
through ↓ visceral pain
Xanthine derivatives 
(e.g. aminophylline 225 mg 
twice daily)
Anti-algogenic effect (due to the direct 
involvement of adenosine in cardiac 
pain generation) 
Vasospastic angina Propensity to 
coronary vasospasm
Vascular smooth muscle  
hyper-reactivity
Calcium channel blockers 
(e.g. amlodipine 10 mg or 
verapamil 240 mg SR)
↓ spontaneous and inducible coronary 
spasm via vascular smooth muscle 
relaxation and ↓ oxygen demand
Nitrates (e.g. isosorbide 
mononitrate XL 30 mg)
↓ spontaneous and inducible coronary 
spasm via large epicardial vasodilation, 
↓ oxygen demand, lack of efficacy in 
microvascular angina with potential 
deleterious effect
Adjunctive non-
pharmacological 
interventions
May be useful in all 
endotypes
Metabolic syndrome, 
endothelial dysfunction, 
cardiovascular risk factors, 
anxiety/depression
Smoking cessation, exercise, 
cardiac rehabilitation, 
Mediterranean diet, cognitive 
behavioural therapy93
ACE = angiotensin converting enzyme; CFR = coronary flow reserve; MVA = microvascular angina; SR = sustained-release preparation.
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calcium channel blockers (non-dihydropyridine and dihydropyridine) 
may be required either alone or in combination. Overall, calcium 
channel blockers are effective in treating >90% of patients.50 
Unfortunately, ankle swelling, constipation and other side-effects may 
render some patients intolerant. Long-term nitrates may be used with 
good efficacy in this group.51 
In about 10% of cases, coronary artery spasm may be refractory 
to optimal vasodilator therapy and require large doses of calcium-
channel blockers or nitrates. Alpha-blockers, e.g. clonidine, may be 
helpful in selected patients with persistent vasospasm. In patients with 
poor nitrate tolerance, the potassium-channel-opener nicorandil can 
be tried. In refractory cases of VSA in patients with acute coronary 
syndrome, coronary angioplasty may be a useful bailout option.52 
In such recalcitrant disease, it is worth reappraising the underlying 
diagnosis and considering coronary vasculitis as a presentation of 
multisystem disease.53
Beyond Pharmacotherapy
The importance of addressing lifestyle factors cannot be 
overemphasised, particularly given that half of the patients in the 
CorMicA study were clinically obese. Strategies to help address this, 
including exercise programmes and cardiac rehabilitation, may help 
facilitate important long-term lifestyle changes.51 Additionally, a new 
diagnosis of angina may increase the use of non-pharmacological 
therapies, including cardiac rehabilitation which may benefit patients 
with ischaemic heart disease.54,55 After clarifying the diagnosis, patients 
may be more motivated to pursue important lifestyle changes, 
including diet, exercise and smoking cessation. We are assessing these 
and longer-term events according to randomised group at 12 months. 
In the CorMicA study, we noted significantly lower illness perception 
scores at 6 months among the intervention arm, representing a less 
threatening view of illness. Angina reduction and improved quality of 
life scores could be in part related to better patient understanding and 
a less threatening perception of the illness. Longitudinal studies of 
other cardiovascular diseases have shown that illness perception is an 
important predictor of longer-term outcomes, including disability and 
returning to work.56 The Objective Randomised Blinded Investigation 
with optimal medical Therapy of Angioplasty in stable angina (ORBITA) 
trial highlights a placebo effect and we support that the positive 
diagnosis may be therapeutic in itself.57 Angina symptoms are often 
subjective and multifactorial in origin, so patient education and 
validation of symptoms may facilitate further improvement.
Future Directions
Our hope is for a personalised medicine approach whereby patients 
with different angina subtypes, defined by the results of coronary 
function tests, may benefit from targeted therapy. Further research 
is needed to determine whether this approach may lead to patient 
benefits. More widespread invasive testing allows identification of 
diagnostic subgroups for the development of targeted therapies 
guided by mechanistic studies. We recently identified systemic vascular 
abnormalities in patients with MVA and VSA, highlighting a potential 
therapeutic role for endothelin-receptor antagonists targeting the 
ETa receptor.58 In addition, Rho-kinase inhibitors represent a potential 
future therapeutic option with anti-effects in patients with excessive 
vascular smooth muscle constriction. More research is needed in well-
defined patients endotypes (subgroups).
Conclusion
Patients with INOCA present a diagnostic and therapeutic challenge 
to physicians. MVA and/or VSA are the two most common causes of 
INOCA and may be overlooked using anatomical coronary tests alone. 
Invasive diagnostic testing permits a positive diagnosis to be made, or 
excluded, during the patients’ index presentation. Correct diagnosis 
of the underlying cause of angina permits stratified treatment of the 
distinct disorders (MVA, VSA or non-cardiac chest pain). CorMicA has 
shown this approach to be safe, feasible with demonstrable benefit 
for patients. 
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